ArticleInternational journal of clinical and experimental medicine2014
Ketamine could aggravate central nervous toxicity of lidocaine in rats convulsive model.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro.Emergency medicine international · 2020Article
- Inhibition of GSK-3beta Signaling Pathway Rescues Ketamine-Induced Neurotoxicity in Neural Stem Cell-Derived Neurons.Neuromolecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies demonstrated that systemic administration of lidocaine could induce central nervous toxicities, including behavioral convulsion as well as cognitive and cellular injury. Ketamine, a general anesthetic, is commonly used as an adjuvant in regional anesthesia with combination of lidocaine. The present was designed to investigate the effects of ketamine in central nervous toxicities of lidocaine. Ketamine (1.2 mg/kg, i.v.) was intravenously injected before and/or after administration of lidocaine in rats. After injection of lidocaine, convulsive behaviors of rats were scored according to the modified Racine scale. Cognitive functions and pathology of hippocampus CA3 pyramid neurons of these rats were evaluated on the one, three, five, and seven days after lidocaine induced convulsion. Both pre- and/or post-administration of ketamine (1.2 mg/kg) could significantly improve lidocaine induced convulsive behaviors of rats (P < 0.01). One, three, five, and seven days after lidocaine induced convulsion, cognitive function and pathology of hippocampus CA3 pyramid neurons of these rats were significantly impaired. In addition, cognitive functions and pathology of neurons of the rats that received ketamine (both pre- and/or post-) were further impaired, compared to the rats without ketamine. We conclude that both pre- and/or post-administration of ketamine could improve lidocaine induced convulsive behaviors. However, cognitive functions and pathology of neurons of these rats are further impaired, compared to the rats without ketamine. This result indicates that ketamine combined with lidocaine might be risky in regional anesthesia.
Indexed as
Identifiers
25664011PMC4307458W2472166047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.